CD274 and triple-negative breast carcinoma: Similarly, the combination of nab-paclitaxel and atezolizumab (anti-PD-L1) was recently approved for triple-negative breast cancer based on a PFS benefit over chemotherapy in the Impassion130 trial.133 These successes have fueled interest, and chemotherapy plus immunotherapy trials are widely available for many cancer subtypes.